Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comparative Effectiveness Bill Allows Industry Input Into Study Selection

This article was originally published in The Gray Sheet

Executive Summary

A bill introduced in the House May 19 would prevent the government from being the sole director of comparative effectiveness research by setting up an independent institute overseen by a broad array of stakeholders, including industry

You may also be interested in...



Long-Time HELP Democrat Sen. Barbara Mikulski Plans To Retire By 2017

Maryland Sen. Barbara Mikulski (D), the body’s longest-serving female Senator, former Appropriations Committee Chair and advocate of quality and comparative effectiveness provisions in the Affordable Care Act, recently announced her plans not to seek re-election in 2016 and retire.

Comparative Effectiveness Research Gets $1.1 Bil.; How Will Data Be Used?

The massive economic stimulus package expected to be signed by President Obama Feb. 16 includes $1.1 billion to promote comparative effectiveness research, but is vague as to what exactly should be studied and how the results should be used

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel